B
TERN

Braidwell’s Terns Pharmaceuticals TERN Stock Holding History

Braidwell’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-575,321
Closed -$23.2M – 98
2025
Q4 		$23.2M Buy
+575,321
New +$13.3M 0.74% 50
2024
Q1 		– Sell
-2,318,050
Closed -$15M – 80
2023
Q4 		$15M Sell
2,318,050
-522,002
-18% -$2.76M 0.55% 49
2023
Q3 		$14.3M Buy
2,840,052
+997,700
+54% +$6.33M 0.45% 68
2023
Q2 		$16.1M Sell
1,842,352
-154,703
-8% -$1.8M 0.53% 58
2023
Q1 		$23.6M Buy
+1,997,055
New +$19.1M 0.78% 48

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Braidwell's TERN Position: Q1 2026 in Review

Braidwell sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 575,321 shares — an estimated $23.2M sold.

Braidwell first reported a position in TERN in Q1 2023 and held it in 5 quarters. The position peaked at $23.6M in Q1 2023. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Braidwell reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Braidwell sold 575,321 Terns Pharmaceuticals shares in Q1 2026, an estimated $23.2M.
  • Braidwell first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Braidwell's Terns Pharmaceuticals position peaked at $23.6M in Q1 2023.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.